(Q33217378)

24 July 2017

1 reference

title

Intrabody applications in neurological disorders: progress and future prospects (English)

1 reference

24 July 2017

Todd W Miller

1

1 reference

24 July 2017

Anne Messer

series ordinal

2

1 reference

24 July 2017

publication date

1 September 2005

1 reference

24 July 2017

1 reference

24 July 2017

volume

12

1 reference

24 July 2017

issue

3

1 reference

24 July 2017

page(s)

394-401

1 reference

Intrabodies: production and promise

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Intrabody and intrakine strategies for molecular therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Intracellular antibodies and challenges facing their use as therapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Atomic force microscopy analysis of the Huntington protein nanofibril formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Strategies for disease modification in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Neurodegenerative tauopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Novel proteinaceous infectious particles cause scrapie

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Molecular mechanisms of neurotoxicity of pathological prion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Scrapie-specific neuronal lesions are independent of neuronal PrP expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Role of the prion protein in copper turnover in astrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Single-chain antigen-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

De novo production of diverse intracellular antibody libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Cloning immunoglobulin variable domains for expression by the polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Yeast surface display for screening combinatorial polypeptide libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Correlation betweenin VitroStability andin VivoPerformance of Anti-GCN4 Intrabodies as Cytoplasmic Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Fast selection of antibodies without antigen purification: adaptation of the protein fragment complementation assay to select antigen-antibody pairs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

The intracellular antibody capture technology: towards the high-throughput selection of functional intracellular antibodies for target validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Generation of a panel of related human scFv antibodies with high affinities for human CEA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Engineering antibody affinity by yeast surface display.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Role of proteolysis in polyglutamine disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Delivery of bioactive molecules into the cell: the Trojan horse approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Stable gene transfer to the nervous system using a non-primate lentiviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Degradation of beta-amyloid by proteolytic antibody light chains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Conformational Abs recognizing a generic amyloid fibril epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Pathogenesis of polyglutamine disorders: aggregation revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Polyglutamine fibrillogenesis: the pathway unfolds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Oligomerization of expanded-polyglutamine domain fluorescent fusion proteins in cultured mammalian cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Huntingtin interacts with a family of WW domain proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Solution Structures of β Peptide and Its Constituent Fragments: Relation to Amyloid Deposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Production of the Alzheimer amyloid beta protein by normal proteolytic processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Neuropathological stageing of Alzheimer-related changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Scrapie protein degradation by cysteine proteases in CD11c+ dendritic cells and GT1-1 neuronal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Molecular biology of prion diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Amyloid fibrils in Gerstmann-Sträussler-Scheinker disease (Indiana and Swedish kindreds) express only PrP peptides encoded by the mutant allele

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Nitration of tau protein is linked to neurodegeneration in tauopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Abnormal tau-containing filaments in neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

USP7, a ubiquitin-specific protease, interacts with ataxin-1, the SCA1 gene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

alpha-Synuclein is phosphorylated in synucleinopathy lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Protein aggregation and neurodegenerative disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Conformation-dependent antibodies target diseases of protein misfolding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.04.003

10.1016/J.YMTHE.2005.04.003

7 January 2021

Identifiers

DOI

1 reference

24 July 2017

1 reference